Access to this article is restricted until 12 months after publication by request of the publisher.. Restriction lift date: 2022-08-03
EAACI guideline: Anaphylaxis (2021 update).
Loading...
Files
Accepted Version
Supporting Information
Date
2021-08-03
Authors
Muraro, A.
Worm, M.
Alviani, C.
Cardona, V.
Dunn Galvin, Audrey
Garvey, L. H.
Riggioni, C.
de Silva, D.
Angier, E.
Arasi, S.
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Inc.
Published Version
Abstract
Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognise and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline. The guideline was developed using the AGREE II framework and the GRADE approach. The evidence was systematically reviewed and recommendations were created by weighing up benefits and harms. The guideline was peer-reviewed by external experts and reviewed in a public consultation. The use of clinical criteria to identify anaphylaxis is suggested with blood sampling for the later measurement of tryptase. The prompt use of intramuscular adrenaline as first line management is recommended with the availability of adrenaline autoinjectors to patients in the community. Pharmacokinetic data should be provided for adrenaline autoinjector devices. Structured, comprehensive training for people at risk of anaphylaxis is recommended. Simulation training and visual prompts for healthcare professionals are suggested to improve the management of anaphylaxis. It is suggested that school policies reflect anaphylaxis guidelines. The evidence for the management of anaphylaxis remains mostly at a very low level. There is an urgent need to prioritise clinical trials with the potential to improve the management of patients at risk of anaphylaxis.
Description
Keywords
Anaphylaxis , Adults , Children , Guidelines
Citation
Muraro, A., Worm, M., Alviani, C., Cardona, V., Dunn Galvin, A., Garvey, L. H., Riggioni, C., de Silva, D., Angier, E., Arasi, S., Bellou, A., Beyer, K., Bijlhout, D., Bilò, M. B., Bindslev-Jensen, C., Brockow, K., Fernandez-Rivas, M., Halken, S., Jensen, B., Khaleva, E., Michaelis, L. J., Oude Elberink, H. N. G., Regent, L., Sanchez, A., Vlieg-Boerstra, B. J. and Roberts, G. (2021) 'EAACI guideline: Anaphylaxis (2021 update)', Allergy. doi: 10.1111/all.15032
Link to publisher’s version
Copyright
© 2020, EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. This is the peer reviewed version of the following article: Muraro, A., Worm, M., Alviani, C., Cardona, V., Dunn Galvin, A., Garvey, L. H., Riggioni, C., de Silva, D., Angier, E., Arasi, S., Bellou, A., Beyer, K., Bijlhout, D., Bilò, M. B., Bindslev-Jensen, C., Brockow, K., Fernandez-Rivas, M., Halken, S., Jensen, B., Khaleva, E., Michaelis, L. J., Oude Elberink, H. N. G., Regent, L., Sanchez, A., Vlieg-Boerstra, B. J. and Roberts, G. (2021) 'EAACI guideline: Anaphylaxis (2021 update)', Allergy, doi: 10.1111/all.15032, which has been published in final form at: https://doi.org/10.1111/all.15032. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.